董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David P. Hochman | 男 | Director | 47 | 8.37万美元 | 未持股 | 2023-08-07 |
| Mark Pomeranz | 男 | Chief Executive Officer and Director | 61 | 51.55万美元 | 未持股 | 2023-08-07 |
| Darren Sherman | 男 | Director | 51 | 6.61万美元 | 未持股 | 2023-08-07 |
| Gary J. Pruden | 男 | Director | 61 | 7.38万美元 | 未持股 | 2023-08-07 |
| Sonja Nelson | 女 | Director | 50 | 6.23万美元 | 未持股 | 2023-08-07 |
| Timothy P. Moran | 男 | Chairman of the Board | 51 | 68.36万美元 | 未持股 | 2023-08-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Pomeranz | 男 | Chief Executive Officer and Director | 61 | 51.55万美元 | 未持股 | 2023-08-07 |
| Ravit Ram | 女 | Chief Financial Officer | 49 | 未披露 | 未持股 | 2023-08-07 |
| Elad Amor | 男 | Chief Accounting Officer | 40 | 未披露 | 未持股 | 2023-08-07 |
董事简历
中英对照 | 中文 | 英文- David P. Hochman
-
David P. Hochman自2013年12月起担任董事。2006年6月他担任Orchestra Medical Ventures有限责任公司（Orchestra Medical Ventures, LLC，一家投资公司，采用创新战略，创建，建设和投资于医疗技术公司，目的是产生大量的临床价值和丰厚的投资者回报）的经营合伙人。他也是Accelerated Technologies股份有限公司（Accelerated Technologies, Inc）的总裁。ATI，是由Orchestra管理着的医疗器械加速器。他在风险资本和投资银行方面有着超过18年的经验。他是Vital Access Corp和MOTUS GI Medical Technologies Ltd的董事长，也是Caliber Therapeutics、BackBeat Medical FreeHold Surgical、Maternity Neighborhood股份有限公司（Maternity Neighborhood, Inc）和Naked Brand Group股份有限公司（Naked Brand Group, Inc（OCT.QB：NAKD））的董事。在加入Orchestra之前，他是Spencer Trask Edison Partners有限责任公司（Spencer Trask Edison Partners, LLC，和创业健康医疗公司是主要投资伙伴关系）的首席执行官。他也是Spencer Trask Ventures股份有限公司（Spencer Trask Edison Partners, LLC）的总经理，在这段期间他负责领导公司的风险银行集团，并引领着20多家创业公司的融资交易。他是Health Dialog Services公司（Health Dialog Services Corporation，一家协同式管理的世界领先者，2008年被British United Provident Association以75亿美元的价格收购）董事会顾问。2005-2007年他担任PROLOR Biotech股份有限公司（PROLOR Biotech, Inc，一家开发批准医疗蛋白的持久版本的生物制药公司，2013年被Opko Health （NYSE： OPK）以60多亿的价格收购）的联合创始人和董事。他目前担任两家非盈利组织的董事会成员：纽约市公民委员会（Citizens Committee for New York City）和Mollie Parnis Livingston Foundation。他以优异的成绩毕业于密歇根大学（University of Michigan）。
David P. Hochman,served as the Chairman of Motus Gi Holdings, Inc. Board from 2016 until 2023, and is the Chairman of the Board of Motus GI Medical Technologies Ltd., Motus Gi Holdings, Inc. wholly owned subsidiary, since 2011. Since May 2018, he has been Chairman and Chief Executive Officer of Orchestra BioMed, Inc.. From 2006 until 2019, he served as Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employed a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company previously managed by Orchestra Medical Ventures, LLC, and now a wholly owned subsidiary of Orchestra BioMed, Inc. Mr. Hochman has over twenty-four years of medical innovation, entrepreneurial, venture capital and investment banking experience. He was a co-founder of Caliber Therapeutics, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and was on the Board of Caliber Therapeutics, Inc. from 2009 until 2018. He was a co-founder of BackBeat Medical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as its President and a member of its Board since inception in 2010 until 2018. He was a co-founder of FreeHold Surgical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as a member of its Board from 2011 until 2018. Mr. Hochman served as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, from 2013 until 2020. He also served as a director of Adgero Biopharmaceuticals Holdings, Inc until 2020 when it was acquired by Kintara Therapeutics, Inc. (NASDAQ: KTRA). Prior to joining Orchestra Medical Ventures LLC, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on development stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc. during which time he led financing transactions for over twenty early-stage companies. From 1999 to 2006 Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013. He is also President and a Board Member of the Mollie Parnis Livingston Foundation, a family foundation. He has a B.A. degree with honors from the University of Michigan. - David P. Hochman自2013年12月起担任董事。2006年6月他担任Orchestra Medical Ventures有限责任公司（Orchestra Medical Ventures, LLC，一家投资公司，采用创新战略，创建，建设和投资于医疗技术公司，目的是产生大量的临床价值和丰厚的投资者回报）的经营合伙人。他也是Accelerated Technologies股份有限公司（Accelerated Technologies, Inc）的总裁。ATI，是由Orchestra管理着的医疗器械加速器。他在风险资本和投资银行方面有着超过18年的经验。他是Vital Access Corp和MOTUS GI Medical Technologies Ltd的董事长，也是Caliber Therapeutics、BackBeat Medical FreeHold Surgical、Maternity Neighborhood股份有限公司（Maternity Neighborhood, Inc）和Naked Brand Group股份有限公司（Naked Brand Group, Inc（OCT.QB：NAKD））的董事。在加入Orchestra之前，他是Spencer Trask Edison Partners有限责任公司（Spencer Trask Edison Partners, LLC，和创业健康医疗公司是主要投资伙伴关系）的首席执行官。他也是Spencer Trask Ventures股份有限公司（Spencer Trask Edison Partners, LLC）的总经理，在这段期间他负责领导公司的风险银行集团，并引领着20多家创业公司的融资交易。他是Health Dialog Services公司（Health Dialog Services Corporation，一家协同式管理的世界领先者，2008年被British United Provident Association以75亿美元的价格收购）董事会顾问。2005-2007年他担任PROLOR Biotech股份有限公司（PROLOR Biotech, Inc，一家开发批准医疗蛋白的持久版本的生物制药公司，2013年被Opko Health （NYSE： OPK）以60多亿的价格收购）的联合创始人和董事。他目前担任两家非盈利组织的董事会成员：纽约市公民委员会（Citizens Committee for New York City）和Mollie Parnis Livingston Foundation。他以优异的成绩毕业于密歇根大学（University of Michigan）。
- David P. Hochman,served as the Chairman of Motus Gi Holdings, Inc. Board from 2016 until 2023, and is the Chairman of the Board of Motus GI Medical Technologies Ltd., Motus Gi Holdings, Inc. wholly owned subsidiary, since 2011. Since May 2018, he has been Chairman and Chief Executive Officer of Orchestra BioMed, Inc.. From 2006 until 2019, he served as Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employed a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Hochman has also served as President of Accelerated Technologies, Inc., a medical device accelerator company previously managed by Orchestra Medical Ventures, LLC, and now a wholly owned subsidiary of Orchestra BioMed, Inc. Mr. Hochman has over twenty-four years of medical innovation, entrepreneurial, venture capital and investment banking experience. He was a co-founder of Caliber Therapeutics, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and was on the Board of Caliber Therapeutics, Inc. from 2009 until 2018. He was a co-founder of BackBeat Medical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as its President and a member of its Board since inception in 2010 until 2018. He was a co-founder of FreeHold Surgical, Inc., a wholly owned subsidiary of Orchestra BioMed, Inc., and served as a member of its Board from 2011 until 2018. Mr. Hochman served as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, from 2013 until 2020. He also served as a director of Adgero Biopharmaceuticals Holdings, Inc until 2020 when it was acquired by Kintara Therapeutics, Inc. (NASDAQ: KTRA). Prior to joining Orchestra Medical Ventures LLC, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on development stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc. during which time he led financing transactions for over twenty early-stage companies. From 1999 to 2006 Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013. He is also President and a Board Member of the Mollie Parnis Livingston Foundation, a family foundation. He has a B.A. degree with honors from the University of Michigan.
- Mark Pomeranz
-
Mark Pomeranz自2018年9月24日起担任首席运营官。在担任我们的首席运营官之前，Pomeranz先生于2016年12月至2018年9月担任我们的首席执行官，并于2014年至2018年9月担任我们的全资子公司Motus Gi Medical Technologies Ltd.的首席执行官。在加入Motus Gi Medical Technologies Ltd.之前，Pomeranz先生于2008年至2014年担任Svelte Medical Systems的创始首席执行官，该公司是一家初创公司，目前正在欧盟商业化独特的药物洗脱支架平台。Pomeranz从2007年到2008年担任Prescient Medical，Inc.研究与开发Vice President。从1998年到2007年，Pomeranz先生担任Cordis公司（一家强生公司公司）的Vice President，他的职责包括开发新技术，探索新的市场机会，并领导重大重组工作，以创建跨职能的全球商业化团队。在此之前，Pomeranz先生曾担任多个高级领导职位，包括1991年至1998年在Cardiac Pathways Corporation和1989年至1991年在Cardiovascular Imaging Systems担任职位，这两家公司均被波士顿科学国际有限公司收购。Pomeranz先生获得了理学硕士学位。the University of Miami生物医学工程学士学位。
Mark Pomeranz,has served as Chief Executive Officer since April 13, 2023. Prior to his appointment to Chief Executive Officer, he served as Chief Operating Officer of the Company since September 24, 2018. Prior to his tenure as Motus Gi Holdings, Inc. Chief Operating Officer, Mr. Pomeranz served as Motus Gi Holdings, Inc. Chief Executive Officer from December 2016 through September 2018, and as the Chief Executive Officer of Motus GI Medical Technologies Ltd., Motus Gi Holdings, Inc. wholly owned subsidiary, from 2014 through September 2018. Prior to joining Motus GI Medical Technologies Ltd., from 2008 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that is currently commercializing a unique drug eluting stent platform. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami. - Mark Pomeranz自2018年9月24日起担任首席运营官。在担任我们的首席运营官之前，Pomeranz先生于2016年12月至2018年9月担任我们的首席执行官，并于2014年至2018年9月担任我们的全资子公司Motus Gi Medical Technologies Ltd.的首席执行官。在加入Motus Gi Medical Technologies Ltd.之前，Pomeranz先生于2008年至2014年担任Svelte Medical Systems的创始首席执行官，该公司是一家初创公司，目前正在欧盟商业化独特的药物洗脱支架平台。Pomeranz从2007年到2008年担任Prescient Medical，Inc.研究与开发Vice President。从1998年到2007年，Pomeranz先生担任Cordis公司（一家强生公司公司）的Vice President，他的职责包括开发新技术，探索新的市场机会，并领导重大重组工作，以创建跨职能的全球商业化团队。在此之前，Pomeranz先生曾担任多个高级领导职位，包括1991年至1998年在Cardiac Pathways Corporation和1989年至1991年在Cardiovascular Imaging Systems担任职位，这两家公司均被波士顿科学国际有限公司收购。Pomeranz先生获得了理学硕士学位。the University of Miami生物医学工程学士学位。
- Mark Pomeranz,has served as Chief Executive Officer since April 13, 2023. Prior to his appointment to Chief Executive Officer, he served as Chief Operating Officer of the Company since September 24, 2018. Prior to his tenure as Motus Gi Holdings, Inc. Chief Operating Officer, Mr. Pomeranz served as Motus Gi Holdings, Inc. Chief Executive Officer from December 2016 through September 2018, and as the Chief Executive Officer of Motus GI Medical Technologies Ltd., Motus Gi Holdings, Inc. wholly owned subsidiary, from 2014 through September 2018. Prior to joining Motus GI Medical Technologies Ltd., from 2008 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that is currently commercializing a unique drug eluting stent platform. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami.
- Darren Sherman
-
Darren Sherman自2011年以来一直担任Motus Gi Medical Technologies Ltd.（我们的全资子公司）的董事，并自2016年12月以来一直担任我们的董事会成员。自2018年5月以来，Sherman先生一直担任Orchestra Biomed，Inc.的总裁，首席运营官和董事会成员，该公司是一家生物医学创新公司，致力于开发高影响治疗解决方案，以解决高危患者可选方案有限或不足的主要医疗状况。Sherman先生在医疗技术行业拥有超过24年的管理和创业经验，涉及介入性心脏病学，心脏电生理学，心脏猝死，中风，外科手术，胃肠道和神经血管疗法。从2009年到2019年12月，Sherman先生担任Orchestra Medical Ventures，LLC的管理合伙人，该公司是一家投资公司，其战略是创建，建立和投资旨在产生可观临床价值的医疗技术公司。Sherman先生还曾担任Accelerated Technologies，Inc.的首席技术官。ATI，由Orchestra Medical Ventures，LLC管理的医疗设备加速器公司，于2008年至2019年，现为Orchestra Biomed，Inc.的全资子公司。从2009年到2018年3月，谢尔曼先生担任Caliber Therapeutics，Inc.的首席执行官兼董事，从2012年到2019年3月，担任Freehold Surgical，Inc.的首席执行官兼董事，从2009年到2019年3月，他曾担任Backbeat Medical，Inc.的董事，每个实体现在都是Orchestra Biomed，Inc.的全资子公司。从2009年到2016年，他曾任职Vivasure Medical Limited公司（医疗设备公司，位于爱尔兰高威）的董事会。在加入Orchestra Medical Ventures，LLC之前，从2002年2月到2008年3月，Sherman先生担任Cordis Neurovascular（CNV）的多个执行管理职位，这是一家强生公司公司，包括中风产品的研发执行总监和战略营销总监。从1997年1月至2002年2月，Sherman先生在Fogarty Engineering工作期间，在Revivant Corp（被Zoll Medical Corporation收购）的形成和发展中发挥了不可或缺的作用。他是Revivant Corp的第一位员工，管理Autopulse设备的设计、开发和测试（从概念到市场介绍）。Sherman从1995年1月到1997年1月在Cardiac Pathways Corp.被Boston Scientific收购之前担任该公司研究与开发职位。任职Cardiac Pathways Corp.之前，他曾任职Baxter梦百合。在这些公司中的每一家，他都参与了产品的创建、开发和推出。Sherman先生撰写了超过七十五项美国专利，并拥有超过九十项其他已发布的申请。他在University of California，San Diego获得生物工程学士学位。
Darren Sherman,has been a director of Motus GI Medical Technologies Ltd., Motus Gi Holdings, Inc. wholly owned subsidiary, since 2011 and has served on Motus Gi Holdings, Inc. Board since December 2016. Since May 2018, Mr. Sherman has been President, Chief Operations Officer and a member of the Board of Orchestra BioMed, Inc.. Mr. Sherman has over 24 years of management and entrepreneurial experience in the medical technology industry spanning interventional cardiology, cardiac electrophysiology, sudden cardiac death, stroke, surgery, GI, and neurovascular therapies. From 2009 until December 2019, Mr. Sherman served as Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employed a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Sherman has also served as Chief Technical Officer of Accelerated Technologies, Inc. (ATI), a medical device accelerator company managed by Orchestra Medical Ventures, LLC, from 2008 to 2019, and now a wholly owned subsidiary of Orchestra BioMed, Inc. From 2009 until March 2018, Mr. Sherman served as Chief Executive Officer and a director of Caliber Therapeutics, Inc., from 2012 until March 2019 served as Chief Executive Officer and a director of FreeHold Surgical, Inc., and from 2009 until March 2019 he served as a director of BackBeat Medical, Inc., each of which entities are now wholly owned subsidiary of Orchestra BioMed, Inc. From 2009 until 2016, he served on the board of directors of Vivasure Medical Limited, a medical device company based in Galway, Ireland. Prior to joining Orchestra Medical Ventures, LLC, from February 2002 until March 2008, Mr. Sherman held various positions in executive management for Cordis Neurovascular (CNV), a Johnson & Johnson company, including Executive Director R&D and Director of Strategic Marketing for stroke products. From January 1997 until February 2002, Mr. Sherman played an integral role in the formation and development of Revivant Corp (acquired by Zoll Medical Corporation) while working at Fogarty Engineering. He was Revivant Corp's first employee and managed the design, development, and testing of the AutoPulse device from concept through market introduction. From January 1995 until January 1997, Mr. Sherman held positions in research and development for Cardiac Pathways Corp., prior to its acquisition by Boston Scientific. Prior to Cardiac Pathways Corp., he worked at Baxter Healthcare. In each of these companies, he participated in the creation, development and launch of products. Mr. Sherman has authored more than eighty-five U.S. patents and has over one-hundred additional published applications. He earned a BS degree in Bioengineering from the University of California, San Diego. - Darren Sherman自2011年以来一直担任Motus Gi Medical Technologies Ltd.（我们的全资子公司）的董事，并自2016年12月以来一直担任我们的董事会成员。自2018年5月以来，Sherman先生一直担任Orchestra Biomed，Inc.的总裁，首席运营官和董事会成员，该公司是一家生物医学创新公司，致力于开发高影响治疗解决方案，以解决高危患者可选方案有限或不足的主要医疗状况。Sherman先生在医疗技术行业拥有超过24年的管理和创业经验，涉及介入性心脏病学，心脏电生理学，心脏猝死，中风，外科手术，胃肠道和神经血管疗法。从2009年到2019年12月，Sherman先生担任Orchestra Medical Ventures，LLC的管理合伙人，该公司是一家投资公司，其战略是创建，建立和投资旨在产生可观临床价值的医疗技术公司。Sherman先生还曾担任Accelerated Technologies，Inc.的首席技术官。ATI，由Orchestra Medical Ventures，LLC管理的医疗设备加速器公司，于2008年至2019年，现为Orchestra Biomed，Inc.的全资子公司。从2009年到2018年3月，谢尔曼先生担任Caliber Therapeutics，Inc.的首席执行官兼董事，从2012年到2019年3月，担任Freehold Surgical，Inc.的首席执行官兼董事，从2009年到2019年3月，他曾担任Backbeat Medical，Inc.的董事，每个实体现在都是Orchestra Biomed，Inc.的全资子公司。从2009年到2016年，他曾任职Vivasure Medical Limited公司（医疗设备公司，位于爱尔兰高威）的董事会。在加入Orchestra Medical Ventures，LLC之前，从2002年2月到2008年3月，Sherman先生担任Cordis Neurovascular（CNV）的多个执行管理职位，这是一家强生公司公司，包括中风产品的研发执行总监和战略营销总监。从1997年1月至2002年2月，Sherman先生在Fogarty Engineering工作期间，在Revivant Corp（被Zoll Medical Corporation收购）的形成和发展中发挥了不可或缺的作用。他是Revivant Corp的第一位员工，管理Autopulse设备的设计、开发和测试（从概念到市场介绍）。Sherman从1995年1月到1997年1月在Cardiac Pathways Corp.被Boston Scientific收购之前担任该公司研究与开发职位。任职Cardiac Pathways Corp.之前，他曾任职Baxter梦百合。在这些公司中的每一家，他都参与了产品的创建、开发和推出。Sherman先生撰写了超过七十五项美国专利，并拥有超过九十项其他已发布的申请。他在University of California，San Diego获得生物工程学士学位。
- Darren Sherman,has been a director of Motus GI Medical Technologies Ltd., Motus Gi Holdings, Inc. wholly owned subsidiary, since 2011 and has served on Motus Gi Holdings, Inc. Board since December 2016. Since May 2018, Mr. Sherman has been President, Chief Operations Officer and a member of the Board of Orchestra BioMed, Inc.. Mr. Sherman has over 24 years of management and entrepreneurial experience in the medical technology industry spanning interventional cardiology, cardiac electrophysiology, sudden cardiac death, stroke, surgery, GI, and neurovascular therapies. From 2009 until December 2019, Mr. Sherman served as Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employed a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value. Mr. Sherman has also served as Chief Technical Officer of Accelerated Technologies, Inc. (ATI), a medical device accelerator company managed by Orchestra Medical Ventures, LLC, from 2008 to 2019, and now a wholly owned subsidiary of Orchestra BioMed, Inc. From 2009 until March 2018, Mr. Sherman served as Chief Executive Officer and a director of Caliber Therapeutics, Inc., from 2012 until March 2019 served as Chief Executive Officer and a director of FreeHold Surgical, Inc., and from 2009 until March 2019 he served as a director of BackBeat Medical, Inc., each of which entities are now wholly owned subsidiary of Orchestra BioMed, Inc. From 2009 until 2016, he served on the board of directors of Vivasure Medical Limited, a medical device company based in Galway, Ireland. Prior to joining Orchestra Medical Ventures, LLC, from February 2002 until March 2008, Mr. Sherman held various positions in executive management for Cordis Neurovascular (CNV), a Johnson & Johnson company, including Executive Director R&D and Director of Strategic Marketing for stroke products. From January 1997 until February 2002, Mr. Sherman played an integral role in the formation and development of Revivant Corp (acquired by Zoll Medical Corporation) while working at Fogarty Engineering. He was Revivant Corp's first employee and managed the design, development, and testing of the AutoPulse device from concept through market introduction. From January 1995 until January 1997, Mr. Sherman held positions in research and development for Cardiac Pathways Corp., prior to its acquisition by Boston Scientific. Prior to Cardiac Pathways Corp., he worked at Baxter Healthcare. In each of these companies, he participated in the creation, development and launch of products. Mr. Sherman has authored more than eighty-five U.S. patents and has over one-hundred additional published applications. He earned a BS degree in Bioengineering from the University of California, San Diego.
- Gary J. Pruden
-
GaryJ.Pruden是董事，审计委员会和薪酬委员会成员，自2018年2月起在董事会任职。Pruden先生在全球梦百合行业有着30多年的经验。最近，Pruden先生于1985年至2017年在强生的医疗器械和制药部门担任了多个高级商业领导职位。2016年4月，普鲁登先生被任命为强生公司执行委员会成员，他的正式头衔是执行Vice President，全球医疗器械董事长。在此之前，他在强生公司担任越来越重要的职务，从2015年到2016年担任医疗器械部门的全球主席，从2012年到2015年担任全球外科集团的全球主席，从2012年到2015年担任Ethicon的公司集团主席，从2009年到2012年担任J&J子公司Ethicon，Inc.的全球总裁，从2006年到2009年担任J&J子公司加拿大Janssen-Ortho Inc.的总裁。Pruden先生还担任过多个职位，包括先进医疗技术协会（Advanced Medical Technology Association）的技术与监管委员会主席和执行委员会成员，该协会是一家医疗设备行业协会。Pruden先生目前担任Motus GiHoldings，Inc.的董事会成员、审计委员会和薪酬委员会成员、Ossio公司的董事会成员和审计委员会主席，以及Avisi Technologies公司的董事会成员。Pruden先生在莱德大学（Rider University）获得金融理学学士学位，在那里他后来从2011年到2015年担任董事会成员。
Gary J. Pruden,has served on Motus Gi Holdings, Inc. Board since December 2017. Prior to joining Motus Gi Holdings, Inc. , from 1985 until 2017, Mr. Pruden held a number of senior commercial leadership positions across both the medical devices and pharmaceutical sectors of Johnson & Johnson (NYSE: JNJ). In April 2004, he became President of the Johnson & Johnson subsidiary, Janssen-Ortho Inc. in Canada. In January 2006, Mr. Pruden was appointed Worldwide President of Ethicon, Inc., a Johnson & Johnson subsidiary, and in 2009 became the Company Group Chairman of Ethicon, Inc. In 2012, he was named Worldwide Chairman of Johnson & Johnson's Global Surgery Group and in 2015 he became Worldwide Chairman in the Medical Devices division. In April 2016, Mr. Pruden became a member of the Executive Committee at Johnson & Johnson where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Mr. Pruden also served in several capacities with the Advanced Medical Technology Association (AdvaMed), a medical device trade association, where he participated in negotiations with the FDA. While at AdvaMed Mr. Pruden served as a member of the board of directors, as chair of the AdvaMed Regulatory Committee, and as a member of the AdvaMed Executive Committee. Mr. Pruden serves as an independent board member for Lantheus Holdings, Inc. (NASDAQ: LNTH) (and serves as a member of its Audit committee and the chair of its Compensation committee), OSSIO Inc, (and serves as the chair of its Audit committee) and Avisi Technologies Inc. Mr. Pruden received his B.S. degree in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015. - GaryJ.Pruden是董事，审计委员会和薪酬委员会成员，自2018年2月起在董事会任职。Pruden先生在全球梦百合行业有着30多年的经验。最近，Pruden先生于1985年至2017年在强生的医疗器械和制药部门担任了多个高级商业领导职位。2016年4月，普鲁登先生被任命为强生公司执行委员会成员，他的正式头衔是执行Vice President，全球医疗器械董事长。在此之前，他在强生公司担任越来越重要的职务，从2015年到2016年担任医疗器械部门的全球主席，从2012年到2015年担任全球外科集团的全球主席，从2012年到2015年担任Ethicon的公司集团主席，从2009年到2012年担任J&J子公司Ethicon，Inc.的全球总裁，从2006年到2009年担任J&J子公司加拿大Janssen-Ortho Inc.的总裁。Pruden先生还担任过多个职位，包括先进医疗技术协会（Advanced Medical Technology Association）的技术与监管委员会主席和执行委员会成员，该协会是一家医疗设备行业协会。Pruden先生目前担任Motus GiHoldings，Inc.的董事会成员、审计委员会和薪酬委员会成员、Ossio公司的董事会成员和审计委员会主席，以及Avisi Technologies公司的董事会成员。Pruden先生在莱德大学（Rider University）获得金融理学学士学位，在那里他后来从2011年到2015年担任董事会成员。
- Gary J. Pruden,has served on Motus Gi Holdings, Inc. Board since December 2017. Prior to joining Motus Gi Holdings, Inc. , from 1985 until 2017, Mr. Pruden held a number of senior commercial leadership positions across both the medical devices and pharmaceutical sectors of Johnson & Johnson (NYSE: JNJ). In April 2004, he became President of the Johnson & Johnson subsidiary, Janssen-Ortho Inc. in Canada. In January 2006, Mr. Pruden was appointed Worldwide President of Ethicon, Inc., a Johnson & Johnson subsidiary, and in 2009 became the Company Group Chairman of Ethicon, Inc. In 2012, he was named Worldwide Chairman of Johnson & Johnson's Global Surgery Group and in 2015 he became Worldwide Chairman in the Medical Devices division. In April 2016, Mr. Pruden became a member of the Executive Committee at Johnson & Johnson where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Mr. Pruden also served in several capacities with the Advanced Medical Technology Association (AdvaMed), a medical device trade association, where he participated in negotiations with the FDA. While at AdvaMed Mr. Pruden served as a member of the board of directors, as chair of the AdvaMed Regulatory Committee, and as a member of the AdvaMed Executive Committee. Mr. Pruden serves as an independent board member for Lantheus Holdings, Inc. (NASDAQ: LNTH) (and serves as a member of its Audit committee and the chair of its Compensation committee), OSSIO Inc, (and serves as the chair of its Audit committee) and Avisi Technologies Inc. Mr. Pruden received his B.S. degree in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015.
- Sonja Nelson
-
Sonja Nelson于2016年5月被任命为我们的首席会计官，并自2015年11月起担任我们的副总裁兼公司财务总监。在加入该公司之前，纳尔逊女士曾担任分子诊断公司Altheadx，Inc.的Vice President兼公司财务总监，并于2014年7月至2015年10月受聘为该公司IPO做准备。此前，纳尔逊女士曾于2012年5月至2014年6月担任CadencePharmaceuticals，Inc.的高级董事兼财务总监。在此之前，Nelson从2008年9月到2012年5月担任Cricket Communications，Inc.（一家价值30亿美元的无线服务提供商）总会计主管。Nelson女士在毕马威会计师事务所（KPMG LLP）开始她的职业生涯，持有德国普福尔茨海姆应用科学大学（University of Applied Sciences）会计和税收学士学位，是一名注册会计师。
Sonja Nelson,has served on Motus Gi Holdings, Inc. Board since June 2021. In June 2021, Ms. Nelson began serving as the Chief Financial Officer of Ambrx Biopharma, Inc, (NASDAQ: AMAM). Prior to that, Ms. Nelson, served as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX), from March 2021 to June 2021. Ms. Nelson served as the Chief Financial Officer of NantKwest, Inc. from June 2018 to March 2021, at which time NantKwest, Inc. merged with ImmunityBio, Inc. (NASDAQ: IBRX). Ms. Nelson previously served as the Chief Accounting Officer of NantKwest, Inc. from May 2016 to June 2018 and as the VP/Corporate Controller of NantKwest, Inc. from November 2015 to May 2016. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc., now merged with ImmunityBio, Inc. (NASDAQ: IBRX)) from October 2017 to June 2021. Prior to joining NantKwest, Inc., Ms. Nelson was Vice President and Corporate Controller at AltheaDx, Inc. from July 2014 through October 2015. Previously, Ms. Nelson was Senior Director and Controller at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc) from May 2012 through June 2014. Prior to that, Ms. Nelson was Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T, Inc.) from September 2008 through May 2012. Ms. Nelson began her career with KPMG LLP, holds a Bachelor's degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany, and is a Certified Public Accountant. - Sonja Nelson于2016年5月被任命为我们的首席会计官，并自2015年11月起担任我们的副总裁兼公司财务总监。在加入该公司之前，纳尔逊女士曾担任分子诊断公司Altheadx，Inc.的Vice President兼公司财务总监，并于2014年7月至2015年10月受聘为该公司IPO做准备。此前，纳尔逊女士曾于2012年5月至2014年6月担任CadencePharmaceuticals，Inc.的高级董事兼财务总监。在此之前，Nelson从2008年9月到2012年5月担任Cricket Communications，Inc.（一家价值30亿美元的无线服务提供商）总会计主管。Nelson女士在毕马威会计师事务所（KPMG LLP）开始她的职业生涯，持有德国普福尔茨海姆应用科学大学（University of Applied Sciences）会计和税收学士学位，是一名注册会计师。
- Sonja Nelson,has served on Motus Gi Holdings, Inc. Board since June 2021. In June 2021, Ms. Nelson began serving as the Chief Financial Officer of Ambrx Biopharma, Inc, (NASDAQ: AMAM). Prior to that, Ms. Nelson, served as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX), from March 2021 to June 2021. Ms. Nelson served as the Chief Financial Officer of NantKwest, Inc. from June 2018 to March 2021, at which time NantKwest, Inc. merged with ImmunityBio, Inc. (NASDAQ: IBRX). Ms. Nelson previously served as the Chief Accounting Officer of NantKwest, Inc. from May 2016 to June 2018 and as the VP/Corporate Controller of NantKwest, Inc. from November 2015 to May 2016. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc., now merged with ImmunityBio, Inc. (NASDAQ: IBRX)) from October 2017 to June 2021. Prior to joining NantKwest, Inc., Ms. Nelson was Vice President and Corporate Controller at AltheaDx, Inc. from July 2014 through October 2015. Previously, Ms. Nelson was Senior Director and Controller at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc) from May 2012 through June 2014. Prior to that, Ms. Nelson was Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T, Inc.) from September 2008 through May 2012. Ms. Nelson began her career with KPMG LLP, holds a Bachelor's degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany, and is a Certified Public Accountant.
- Timothy P. Moran
-
TimothyP.Moran自2018年10月1日起担任首席执行官。在加入我们之前，莫兰先生于2015年至2018年9月担任国际医疗产品和技术公司Convatec Group plc Lon:CTEC（“；Convatec”；）的美洲总裁，提供伤口和皮肤护理，造口护理，失禁和危重护理及输液器。在Convatec任职之前，Moran先生在Covidien plc（“；Covidien”；）担任了18年的销售，营销和综合管理职务，这是一家总部位于爱尔兰的全球医疗保健产品公司以及医疗设备和用品制造商。在Covidien任职期间，直到2015年，Moran先生同时担任SharpSafety和Monitoring&Operating Room部门的副总裁兼总经理。在2015年美敦力（纽约证券交易所代码:MDT）收购Covidien之后，莫兰先生被任命为全球Vice President兼患者护理和安全部门总经理。Moran先生还曾任职于Advanced Medical Technology Association（ADVAMED）的首席执行官咨询委员会，这是一家医疗设备贸易协会。Moran先生在纽约州立大学日内瓦分校（State University of New York at Geneseo）获得组织传播学学士学位。
Timothy P. Moran,was appointed Chairman of the Board on April 13, 2023. Prior to his appointment to Chairman of the Board, Mr. Moran served as Chief Executive Officer of the Company since October 1, 2018. Prior to joining Motus Gi Holdings, Inc. , from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) ("ConvaTec"), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Covidien plc ("Covidien"), an Irish-headquartered global health care products company and manufacturer of medical devices and supplies. While at Covidien, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo. - TimothyP.Moran自2018年10月1日起担任首席执行官。在加入我们之前，莫兰先生于2015年至2018年9月担任国际医疗产品和技术公司Convatec Group plc Lon:CTEC（“；Convatec”；）的美洲总裁，提供伤口和皮肤护理，造口护理，失禁和危重护理及输液器。在Convatec任职之前，Moran先生在Covidien plc（“；Covidien”；）担任了18年的销售，营销和综合管理职务，这是一家总部位于爱尔兰的全球医疗保健产品公司以及医疗设备和用品制造商。在Covidien任职期间，直到2015年，Moran先生同时担任SharpSafety和Monitoring&Operating Room部门的副总裁兼总经理。在2015年美敦力（纽约证券交易所代码:MDT）收购Covidien之后，莫兰先生被任命为全球Vice President兼患者护理和安全部门总经理。Moran先生还曾任职于Advanced Medical Technology Association（ADVAMED）的首席执行官咨询委员会，这是一家医疗设备贸易协会。Moran先生在纽约州立大学日内瓦分校（State University of New York at Geneseo）获得组织传播学学士学位。
- Timothy P. Moran,was appointed Chairman of the Board on April 13, 2023. Prior to his appointment to Chairman of the Board, Mr. Moran served as Chief Executive Officer of the Company since October 1, 2018. Prior to joining Motus Gi Holdings, Inc. , from 2015 to September 2018, Mr. Moran served as President of the Americas, ConvaTec Group Plc (LON: CTEC) ("ConvaTec"), an international medical products and technologies company, offering products and services in the areas of wound and skin care, ostomy care, continence and critical care and infusion devices. Prior to his employment at ConvaTec, Mr. Moran held roles in sales, marketing and general management over the course of eighteen years at Covidien plc ("Covidien"), an Irish-headquartered global health care products company and manufacturer of medical devices and supplies. While at Covidien, until 2015, Mr. Moran served simultaneously as VP and General Manager of both the SharpSafety and Monitoring & Operating Room divisions. Following the 2015 acquisition of Covidien by Medtronic (NYSE:MDT), Mr. Moran was named the Global Vice President and General Manager of the Patient Care and Safety Division. Mr. Moran also served on the CEO Advisory Council for Advanced Medical Technology Association (AdvaMed), a medical device trade association. Mr. Moran earned a B.A. in Organizational Communication at The State University of New York at Geneseo.
高管简历
中英对照 | 中文 | 英文- Mark Pomeranz
Mark Pomeranz自2018年9月24日起担任首席运营官。在担任我们的首席运营官之前，Pomeranz先生于2016年12月至2018年9月担任我们的首席执行官，并于2014年至2018年9月担任我们的全资子公司Motus Gi Medical Technologies Ltd.的首席执行官。在加入Motus Gi Medical Technologies Ltd.之前，Pomeranz先生于2008年至2014年担任Svelte Medical Systems的创始首席执行官，该公司是一家初创公司，目前正在欧盟商业化独特的药物洗脱支架平台。Pomeranz从2007年到2008年担任Prescient Medical，Inc.研究与开发Vice President。从1998年到2007年，Pomeranz先生担任Cordis公司（一家强生公司公司）的Vice President，他的职责包括开发新技术，探索新的市场机会，并领导重大重组工作，以创建跨职能的全球商业化团队。在此之前，Pomeranz先生曾担任多个高级领导职位，包括1991年至1998年在Cardiac Pathways Corporation和1989年至1991年在Cardiovascular Imaging Systems担任职位，这两家公司均被波士顿科学国际有限公司收购。Pomeranz先生获得了理学硕士学位。the University of Miami生物医学工程学士学位。
Mark Pomeranz,has served as Chief Executive Officer since April 13, 2023. Prior to his appointment to Chief Executive Officer, he served as Chief Operating Officer of the Company since September 24, 2018. Prior to his tenure as Motus Gi Holdings, Inc. Chief Operating Officer, Mr. Pomeranz served as Motus Gi Holdings, Inc. Chief Executive Officer from December 2016 through September 2018, and as the Chief Executive Officer of Motus GI Medical Technologies Ltd., Motus Gi Holdings, Inc. wholly owned subsidiary, from 2014 through September 2018. Prior to joining Motus GI Medical Technologies Ltd., from 2008 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that is currently commercializing a unique drug eluting stent platform. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami.- Mark Pomeranz自2018年9月24日起担任首席运营官。在担任我们的首席运营官之前，Pomeranz先生于2016年12月至2018年9月担任我们的首席执行官，并于2014年至2018年9月担任我们的全资子公司Motus Gi Medical Technologies Ltd.的首席执行官。在加入Motus Gi Medical Technologies Ltd.之前，Pomeranz先生于2008年至2014年担任Svelte Medical Systems的创始首席执行官，该公司是一家初创公司，目前正在欧盟商业化独特的药物洗脱支架平台。Pomeranz从2007年到2008年担任Prescient Medical，Inc.研究与开发Vice President。从1998年到2007年，Pomeranz先生担任Cordis公司（一家强生公司公司）的Vice President，他的职责包括开发新技术，探索新的市场机会，并领导重大重组工作，以创建跨职能的全球商业化团队。在此之前，Pomeranz先生曾担任多个高级领导职位，包括1991年至1998年在Cardiac Pathways Corporation和1989年至1991年在Cardiovascular Imaging Systems担任职位，这两家公司均被波士顿科学国际有限公司收购。Pomeranz先生获得了理学硕士学位。the University of Miami生物医学工程学士学位。
- Mark Pomeranz,has served as Chief Executive Officer since April 13, 2023. Prior to his appointment to Chief Executive Officer, he served as Chief Operating Officer of the Company since September 24, 2018. Prior to his tenure as Motus Gi Holdings, Inc. Chief Operating Officer, Mr. Pomeranz served as Motus Gi Holdings, Inc. Chief Executive Officer from December 2016 through September 2018, and as the Chief Executive Officer of Motus GI Medical Technologies Ltd., Motus Gi Holdings, Inc. wholly owned subsidiary, from 2014 through September 2018. Prior to joining Motus GI Medical Technologies Ltd., from 2008 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that is currently commercializing a unique drug eluting stent platform. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami.
- Ravit Ram
Ravit Ram，自2023年6月起担任Motus Gi Holdings, Inc.首席财务官。在此之前，拉姆女士自2018年加入公司以来一直担任公司全球运营和财务副总裁。在加入公司之前，拉姆女士曾在EndoChoice担任财务、供应链和网站经理，管理EndoChoice Israeli的网站财务、供应链和IT部门。此前，她曾在Given Imaging担任全球运营总监，负责该公司全球运营和研发活动的所有财务方面。拉姆在巴伊兰大学获得了金融和社会学学士学位，在海法大学获得了精算师硕士学位。
Ravit Ram,has served as Motus Gi Holdings, Inc. Chief Financial Officer since June 2023. Prior to this, Ms. Ram served as the Company's Vice President of Global Operations and Finance since joining the Company in 2018. Prior to joining the Company, Ms. Ram served as the Director of Finance, supply chain, and site manager at EndoChoice, managing EndoChoice Israeli's site finance, supply chain, and IT departments. Earlier, she served as Global Director Operation Controller at Given Imaging, where she was responsible for all financial aspects of the company's global operations and R&D activities. Ms. Ram earned her B.A. in Finance and Sociology at 'Bar Ilan' University and M.A. in Actuary at Haifa University.- Ravit Ram，自2023年6月起担任Motus Gi Holdings, Inc.首席财务官。在此之前，拉姆女士自2018年加入公司以来一直担任公司全球运营和财务副总裁。在加入公司之前，拉姆女士曾在EndoChoice担任财务、供应链和网站经理，管理EndoChoice Israeli的网站财务、供应链和IT部门。此前，她曾在Given Imaging担任全球运营总监，负责该公司全球运营和研发活动的所有财务方面。拉姆在巴伊兰大学获得了金融和社会学学士学位，在海法大学获得了精算师硕士学位。
- Ravit Ram,has served as Motus Gi Holdings, Inc. Chief Financial Officer since June 2023. Prior to this, Ms. Ram served as the Company's Vice President of Global Operations and Finance since joining the Company in 2018. Prior to joining the Company, Ms. Ram served as the Director of Finance, supply chain, and site manager at EndoChoice, managing EndoChoice Israeli's site finance, supply chain, and IT departments. Earlier, she served as Global Director Operation Controller at Given Imaging, where she was responsible for all financial aspects of the company's global operations and R&D activities. Ms. Ram earned her B.A. in Finance and Sociology at 'Bar Ilan' University and M.A. in Actuary at Haifa University.
- Elad Amor
Elad Amor，自2023年6月起担任Motus Gi Holdings, Inc.首席会计官。在此之前，Amor先生曾担任公司全球财务和会计总监，负责监督公司全球会计职能的所有方面，以及内部和外部财务报告的编制。在2019年加入公司之前，Amor先生是Kaleido Biosciences会计和证交会报告副主任。在此之前的2016-2019年，他在CRISPR Therapeutics公司担任SEC报告和技术会计经理，负责准备和监督所有公开文件的准备工作。Amor先生是一名注册会计师，在东北大学获得会计学硕士学位和工商管理硕士学位，并在威斯康星大学获得遗传学学士学位。
Elad Amor,has served as Motus Gi Holdings, Inc. Chief Accounting Officer since June 2023. Prior to this, Mr. Amor served as the Company's Global Director of Corporate Finance and Accounting, where he oversaw all facets of the Company's global accounting functions, as well as the preparation of internal and external financial reporting. Prior to joining the Company in 2019, Mr. Amor was the Associate Director of Accounting and SEC Reporting at Kaleido Biosciences. Earlier, from 2016-2019, he served as the Manager of SEC Reporting and Technical Accounting at CRISPR Therapeutics AG, where he was responsible for preparing and overseeing the preparation of all public filings. Mr. Amor is a certified public accountant and earned his Master of Science in Accounting and Master of Business Administration from Northeastern University, as well as a BS in Genetics from the University of Wisconsin.- Elad Amor，自2023年6月起担任Motus Gi Holdings, Inc.首席会计官。在此之前，Amor先生曾担任公司全球财务和会计总监，负责监督公司全球会计职能的所有方面，以及内部和外部财务报告的编制。在2019年加入公司之前，Amor先生是Kaleido Biosciences会计和证交会报告副主任。在此之前的2016-2019年，他在CRISPR Therapeutics公司担任SEC报告和技术会计经理，负责准备和监督所有公开文件的准备工作。Amor先生是一名注册会计师，在东北大学获得会计学硕士学位和工商管理硕士学位，并在威斯康星大学获得遗传学学士学位。
- Elad Amor,has served as Motus Gi Holdings, Inc. Chief Accounting Officer since June 2023. Prior to this, Mr. Amor served as the Company's Global Director of Corporate Finance and Accounting, where he oversaw all facets of the Company's global accounting functions, as well as the preparation of internal and external financial reporting. Prior to joining the Company in 2019, Mr. Amor was the Associate Director of Accounting and SEC Reporting at Kaleido Biosciences. Earlier, from 2016-2019, he served as the Manager of SEC Reporting and Technical Accounting at CRISPR Therapeutics AG, where he was responsible for preparing and overseeing the preparation of all public filings. Mr. Amor is a certified public accountant and earned his Master of Science in Accounting and Master of Business Administration from Northeastern University, as well as a BS in Genetics from the University of Wisconsin.